Idorsia Implements ³Ô¹Ï±¬ÁÏ Development Cloud in Less Than 12 Months
Unified applications for clinical, regulatory, and quality help fast-growing start-up drive greater efficiency and compliance throughout development
PLEASANTON, CA ¡ª July 10, 2018 ¡ª ³Ô¹Ï±¬ÁÏ Systems (NYSE:VEEV) today announced that Idorsia Pharmaceuticals Ltd established an integrated development landscape with ³Ô¹Ï±¬ÁÏ Development Cloud. With unified applications for clinical, regulatory, and quality on a single cloud platform, Idorsia now has the technology foundation to accelerate product innovation and support its global growth plans.
¡°With a strong pipeline of innovative new therapies, we needed cutting-edge cloud technology that could scale as we grow,¡± said Joseph Bejjani, CIO at Idorsia. ¡°Our IT strategy had three guiding principles when it came to product selection ¨C cloud-first, easy-to-use functionality, and integrated, platform-based solutions. ³Ô¹Ï±¬ÁÏ met all three objectives within a very tight timeline.¡±
Idorsia is a fast-growing biopharmaceutical start-up focused on research and early-stage clinical development. Immediately after its founding, Idorsia set an aggressive timeline to transition to new clinical development systems within 12 months.
With ³Ô¹Ï±¬ÁÏ Development Cloud, Idorsia has unified applications to streamline documents and workflows so teams have a single source of truth across clinical, regulatory, and quality. This eliminates manual, duplicative efforts and gives teams consistent information throughout clinical development. Because ³Ô¹Ï±¬ÁÏ Vault applications have the same modern and intuitive interface, teams work with greater speed and spend less time on training.
¡°³Ô¹Ï±¬ÁÏ gives us the right technology foundation to manage business processes, content, and data across the organization,¡± said Simone Mechler, associate director clinical & quality systems. ¡°We exceeded our goal and went live within seven months. All regions and departments now have a consistent view of the products in development to drive greater operational efficiency and maintain compliance.¡±
Idorsia is using or plans to use multiple applications across ³Ô¹Ï±¬ÁÏ Development Cloud suites, including Vault eTMF and Vault CTMS from Vault Clinical Suite; Vault Registrations, Vault Submissions, and Vault Submissions Publishing from Vault RIM Suite; and Vault QMS and Vault QualityDocs from Vault Quality Suite.
¡°Idorsia needed to bring together their applications for clinical, quality, and regulatory to streamline drug development,¡± said Rik Van Mol, vice president, R&D strategy, Europe at ³Ô¹Ï±¬ÁÏ. ¡°³Ô¹Ï±¬ÁÏ Development Cloud helps life sciences companies like Idorsia achieve alignment across headquarters, sites, and countries and increases communication, collaboration, and compliance across the functions.¡±
Additional Information
For more on ³Ô¹Ï±¬ÁÏ Development Cloud, visit: veeva.com/³Ô¹Ï±¬ÁÏDevelopmentCloud
Connect with ³Ô¹Ï±¬ÁÏ on LinkedIn:
Follow @veevasystems on Twitter:
Like ³Ô¹Ï±¬ÁÏ on Facebook:
About ³Ô¹Ï±¬ÁÏ Systems
³Ô¹Ï±¬ÁÏ Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, ³Ô¹Ï±¬ÁÏ has more than 625 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. ³Ô¹Ï±¬ÁÏ is headquartered in the San Francisco Bay Area, with offices in Europe, Asia, and Latin America. For more information, visit veeva.com.
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of ³Ô¹Ï±¬ÁÏ¡¯s products and services, the results from use of ³Ô¹Ï±¬ÁÏ¡¯s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon ³Ô¹Ï±¬ÁÏ¡¯s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent ³Ô¹Ï±¬ÁÏ¡¯s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and ³Ô¹Ï±¬ÁÏ disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect ³Ô¹Ï±¬ÁÏ¡¯s financial results are included under the captions, ¡°Risk Factors¡± and ¡°Management¡¯s Discussion and Analysis of Financial Condition and Results of Operations,¡± in the company¡¯s filing on Form 10-Q for the period ended April 30, 2018. This is available on the company¡¯s website at veeva.com under the Investors section and on the SEC¡¯s website at . Further information on potential risks that could affect actual results will be included in other filings ³Ô¹Ï±¬ÁÏ makes with the SEC from time to time.
###
Contact:
³Ô¹Ï±¬ÁÏ Systems
pr@veeva.com